Why the study?
This study aimed to evaluate the effects of cardiac contractility modulation (CCM) on structural and electrical remodeling in a rabbit model of chronic heart failure.
Does cardiac contractility modulation attenuate structural and electrical remodeling in a rabbit model of chronic heart failure?
Does cardiac contractility modulation attenuate structural and electrical remodeling in a rabbit model of chronic heart failure?
Cardiac contractility modulation attenuates myocardial structural and electrical remodeling in a rabbit model of chronic heart failure, providing preclinical mechanistic support for its clinical use.
Answers are grounded in this paper and cite their sources.
CCM may attenuate remodeling in experimental CHF; leaves open translation to clinical therapy.
BACKGROUND: Cardiac contractility modulation (CCM) is non-excitatory electrical stimulation for improving cardiac function. This study aimed to evaluate the effects of CCM on structural and electrical remodeling in a rabbit model of chronic heart failure (CHF). METHODS: Thirty rabbits were randomly divided into the sham, CHF, and CCM groups. The CHF model was induced 12 weeks after trans-aortic constriction by pressure unloading and CCM was delivered to the myocardium for 4 weeks. Corrected QT intervals, the ventricular effective refractory period, and inducibility of ventricular tachycardia were measured by an electrophysiological examination. Connective tissue growth factor, galectin-3, Kv4.3, KCNQ1, KCNH2, and connexin 43 protein levels were measured by western blotting. RESULTS: The CHF group had a significantly prolonged corrected QT interval and ventricular effective refractory period, and increased inducibility of ventricular tachycardia. Prominent myocardial fibrosis and increased hydroxyproline content were observed in the CHF group, but these were suppressed in the CCM group. Kv4.3, KCNQ1, KCNH2, and connexin 43 protein levels were significantly lower in the CHF group, but treatment with CCM partially restored their levels. CONCLUSIONS: CCM attenuates myocardial structural and electrical remodeling during CHF. These findings provide evidence for clinical use of CCM in treating CHF.
No takes yet. Share an insight, caveat, or question.
Ning et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: